AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01459367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
Study NCT01459367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks.
Study NCT00382915 — intervention group
Intervention type: DEVICE
Intervention: CReSSmicro handheld topography device
Description: The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
Study NCT00569439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D10NS
Description: 10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study NCT00598663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)
Description: 6 months of pump plus continuous glucose sensing in conjunction to SMBG
Study NCT00598663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
Description: insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
Study NCT00720057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
Study NCT00720057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
Study NCT00641862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
Study NCT00641862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
Study NCT01892501 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Guided punction of mediastinal lymphadenopathy by echoendoscopy
Description: EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken.
Study NCT01892501 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET scan
Description: The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
Study NCT04443504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Connected Family Series
Description: The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
Study NCT03505944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: venetoclax + lenalidomide + rituximab
Study NCT02671279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low calorie diet
Description: 6 days of low calorie diet, estimated kcal 400-600/day.
Study NCT01032876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Hypothermic Circulatory Arrest
Description: DHCA will be employed for a maximum of 60 minutes. If more time (>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
Study NCT01032876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antegrade Cerebral Perfusion
Description: One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
Study NCT01733407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-serine
Description: 400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
Study NCT01733407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 400mg/kg/d divided TID for year 1 only.
Study NCT00569439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS
Description: Normal Saline solution at 125 cc/hr
Study NCT03096470 — intervention group
Intervention type: PROCEDURE
Intervention: anesthesia
Description: no anesthesia
Study NCT03630549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Clinic-based HIV care
Study NCT03630549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village-based ART refill
Description: Option to get ART refill and care by the village health worker
Study NCT04252638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy plus Sleep Restriction
Description: Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
Study NCT04252638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy including Sleep Restriction
Description: CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
Study NCT02105571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study NCT00979004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICA-105665
Description: Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
Study NCT02808273 — intervention group
Intervention type: DRUG
Intervention: Bemiparine
Description: Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
Study NCT00215904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D-serine (~2g/day)
Description: Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
Study NCT00215904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine (~2g/day)
Description: Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
Study NCT03513432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beer with 5.20 % alcohol
Description: 330 ml beer (5.20 % alcohol)/day during 4 weeks
Study NCT03513432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer with 0.45 % alcohol
Description: 330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
Study NCT03513432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer with 0.00 % alcohol
Description: 330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
Study NCT02714894 — intervention group
Intervention type: DRUG
Intervention: Clozapine
Description: Patient participants will be starting clozapine as part of their clinical care.
Study NCT01843933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capnography
Description: Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
Study NCT03799523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporary skin markings
Description: To use temporary markings in lieu of localization tattoos.
Study NCT03799523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface imaging
Description: To use light-based surface imaging for patient positioning during radiation treatment.
Study NCT02411994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Study NCT02411994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Study NCT02116192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Low-fructose, reduced carbohydrate diet
Description: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily.
Study NCT02116192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Healthy Diet
Description: Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
Study NCT02659839 — intervention group
Intervention type: OTHER
Intervention: Cancer patients admitted to the ICU
Description: There will be no change in the standard ICU treatment.
Study NCT03276494 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraosseous
Description: Intraosseous administration of hypertonic saline
Study NCT03276494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hypertonic saline
Description: Intraosseous administration of hypertonic saline
Study NCT00018694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chenodeoxycholic Acid
Study NCT01070381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A contact lens
Description: Commercially marketed, toric, soft contact lens for daily disposable wear
Study NCT01070381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D contact lens
Description: Commercially marketed, toric, soft contact lens for daily disposable wear
Study NCT01869686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg
Study NCT03115164 — intervention group
Intervention type: OTHER
Intervention: To study the characteristics of patients with DIA / DIG
Description: Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
Study NCT00006242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV
Study NCT00006242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00006242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00598884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Self-Management for Prolonged Grief Symptoms
Description: The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
Study NCT03864016 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adaptation of sufentanil doses according to the usual protocol
Description: At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
Study NCT03864016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjustment of sufentanil doses according to pupillometry
Description: At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
Study NCT02197910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)
Study NCT02197910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)
Study NCT05640505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School based Gratitude Interventions
Description: Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
Study NCT00234000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
Study NCT00234000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
Study NCT02184767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADASUVE®
Description: ADASUVE® 2.5, 5, or 10 mg
Study NCT02354625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous human Schwann cells
Description: Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
Study NCT04597931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: SC Romosozumab 210 mg/monthly
Study NCT04597931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: IV Zoledronic acid 5 mg
Study NCT01246804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir single dose
Description: single dose 400mg raltegravir
Study NCT01246804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir single dose
Description: single dose 400mg raltegravir
Study NCT01246804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginkgo biloba multiple dose
Description: 15 days ginkgo biloba 120mg BID
Study NCT02018965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Niacin
Description: • Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study.
Study NCT01230970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495
Description: 40mg tablet oral daily administration from Day 1 to Day 14.
Study NCT04370561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF non-locking
Description: Open reduction and internal fixation using 1/3 tubular plate
Study NCT04459858 — intervention group
Intervention type: OTHER
Intervention: data analysis
Description: Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined.
Study NCT01259388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
Study NCT04226365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: 10mg capsule Nortryptyline
Study NCT04226365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg capsule Thick-It filler
Study NCT00384982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cells implantation
Description: percutaneous BM-derived cell therapy
Study NCT04370561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF locking
Description: Open reduction and internal fixation using active ankle polyaxial locking plate
Study NCT02018965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Niacin
Description: • Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study.
Study NCT00890851 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transurethral Needle Ablation (TUNA)
Description: Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
Study NCT02543879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-1101
Description: FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
Study NCT03935555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
Study NCT01710735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Insertion of acupuncture needle into a myofascial trigger point.
Study NCT01710735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Insertion of acupuncture needle into a myofascial trigger point.
Study NCT01862835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT01862835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Study NCT01862835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT01862835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Study NCT02867774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine.
Study NCT01452295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELAD (Extracorporeal Liver Assist System)
Description: ELAD (Extracorporeal Liver Assist System)
Study NCT02817347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
Study NCT02817347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
Study NCT02817347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 2% + tazobactam 0.25%